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ABSTRACT
Fibroblast growth factor 23 (FGF-23) is likely to be the most important regulator of phosphate homeostasis, which mediates its functions
through FGF receptors and the coreceptor Klotho. Besides reducing expression of the sodium-phosphate cotransporters NPT2a and
NPT2c in the proximal tubules, FGF-23 inhibits the renal 1a-hydroxylase and stimulates the 24-hydroxylase, and it appears to reduce
parathyroid hormone (PTH) secretion in short-term studies. FGF-23 synthesis and secretion by osteocytes and osteoblasts is upregulated
through 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and through an increased dietary phosphate intake. FGF-23 levels are elevated or
inappropriately normal in patients with tumor-induced osteomalacia and several inherited hypophosphatemic disorders, but the most
significant increases are found in patients with chronic kidney disease (CKD). During the early stages of CKD, increased FGF-23
production enhances urinary phosphate excretion and thus prevents the development of hyperphosphatemia, reduces the circulating
levels of 1,25(OH)2D3, and therefore contributes to the development of secondary hyperparathyroidism. In patients with end-stage renal
disease (ESRD), FGF-23 levels can be extremely high and were shown to be predictors of bone mineralization, left ventricular
hypertrophy, vascular calcification, and mortality. It remains to be determined, however, whether FGF-23 represents simply a sensitive
biomarker of an abnormal phosphate homeostasis or has, independent of serum phosphate levels, potentially negative ‘‘off-target’’
effects.Nonetheless,reducingtheproductionand/orthebiologicactivityofFGF-23maybeanimportanttherapeuticgoalforthispatient
population.  2010 American Society for Bone and Mineral Research.
KEY WORDS: PTH; 1,25(OH)2D3; FGF-23; PHOSPHATE HOMEOSTASIS; CHRONIC KIDNEY DISEASE; BONE MINERALIZATION; CARDIOVASCULAR DISEASE
Introduction
P
arathyroid hormone (PTH) and active vitamin D metabolites
are the most important regulators of calcium homeostasis,
and much knowledge regarding their mode of actions has
accumulated over several decades.
(1–3) PTH also affects phos-
phate homeostasis through its actions on kidney and bone,
whereas 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], which is
generated from the precursor 25-hydroxyvitamin D through
the renal 1a-hydroxylase, contributes to intestinal phosphate
absorption.
(3) However, both hormones are not the only and
probably not the most important hormonal regulators of
phosphate homeostasis. Considerable advances that contribu-
ted to a much improved understanding of the regulation of
phosphatehomeostasisweremadeoverthelastdecadethrough
the molecular definition of rare inherited disorders characterized
by either hypo- or hyperphosphatemia and through studies of
rare tumors that cause urinary phosphate wasting (for review,
see refs.
(4 through 7)). These efforts have resulted in the discovery
of fibroblast growth factor 23 (FGF-23), which is likely the most
important phosphate-regulating hormone.
(8,9) Furthermore,
several other genes were identified that contribute importantly
to the regulation of FGF-23 synthesis and secretion, or facilitate
high-affinity receptor binding and signal transduction in target
cells.Itisalmostcertain,however,thatadditionalgenesexistthat
contribute importantly to these regulatory processes.
Besides its important role in regulating renal phosphate ex-
cretion and thus serum phosphate concentration in healthy
individuals,thereisgrowingevidencetosuggestthatFGF-23has
an important role in maintaining normal blood phosphate levels
during the early stages of chronic kidney disease (CKD) by aug-
menting per-nephron urinary phosphate excretion. Moreover,
elevated FGF-23 levels were found to predict rapid progression
of kidney disease, and among patients with end-stage renal
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2091disease (ESRD) treated with dialysis, FGF-23 levels were
associated with abnormal bone metabolism.
(10) left ventricular
hypertrophy and mass index,
(11) vascular calcifications,
(12) and
increased mortality.
(13,14) FGF-23 thus appears to have an
important role as a biomarker in CKD patients, and measuring
FGF-23 levels is likely to provide a sensitive diagnostic tool for
assessing phosphate homeostasis and possibly its detrimental
‘‘off-target’’ effects. FGF-23 may thus constitute an important
target for therapeutic interventions in the different stages of
CKD.
FGF-23: An Important Regulator of
Phosphate Homeostasis
FGF-23 was first identified in mouse embryonic tissue by
homology-based hybridization techniques.
(15) However, its
important role in phosphate homeostasis became apparent
only when gain-of-function mutations in FGF23 were shown to
cause autosomal dominant hypophosphatemic rickets (ADHR)
(8)
and when FGF-23, independently isolated from tumors that
cause hypophosphatemia and consequently osteomalacia
owing to renal phosphate wasting [tumor-induced osteomalacia
(TIO)], was shown to increase renal phosphate excretion.
(9) The
human FGF23 gene on chromosome 12p13.3 encodes a
glycoprotein consisting of 251 amino acid residues, including
a leader sequence of 24 residues that is cleaved off before
secretion into the circulation. FGF-23 undergoes O-glycosylation
by UDP-N-acetyl-a-D-galactosamine:polypeptide N-acetylgalac-
tosaminyl-transferase 3 (GALNT3), most likely involving amino
acid residue 178.
(16) This posttranslational modification protects
FGF-23 from cleavage by subtilisin-like proprotein conver-
tases.
(17) Consequently, inactivating mutations in GALNT3 or
FGF23 that prevent normal O-glycosylation of FGF-23 leading
to the synthesis of an unmodified molecule,
(18) which results
in impaired secretion of intact but not C-terminal FGF-23.
(18–21)
O-glycosylation is thus required for secretion of intact, bio-
logically active FGF-23.
(21)
Osteocytes and osteoblasts are the main source of FGF-23,
(22–
24) but low levels of uncertain significance are also detected at
the transcriptional level intheventrolateral thalamicnucleus, the
thymus, the small intestine, and the heart.
(25) Several proteins
appear to suppress the synthesis and secretion of FGF-23,
including phosphate-regulating protein with homology to
endopeptidases on the X chromosome (PHEX), dentin matrix
protein 1 (DMP1), and ectonucleotide pyrophosphatase/phos-
phodiesterase 1 (ENPP1)
(4–7,26,27) (Fig. 1, left panel). The most
important stimulators of FGF-23 synthesis appear to be dietary
phosphate
(28–30) and 1,25(OH)2D3,
(31) but other agents, such as
some iron formulations, also may increase its production.
(32–34)
However, owingtothelackofsuitable celllines,itso farhasbeen
impossible to study in detail the regulation of FGF-23 synthesis
and secretion and the impact of different pharmacological
agents.
FGF-23 mediates its phosphate-regulating properties through
different FGF receptors (FGFRs), most prominently through
FGFR1c; these actions require a-Klotho (KL) as coreceptor.
(35,36)
However, the site(s) of FGF-23 action in the kidney remains
controversial. FGF-23 decreases expression of NPT2a and
NPT2c,
(37,38) it decreases the activity of the 1a-hydroxylase,
and it increases the activity of the 24-hydroxylase inthe proximal
tubules.
(6,39) However, the coreceptor Klotho, which is essential
Fig. 1. Regulation of phosphate homeostasis in health and chronic kidney disease (CKD). (A) FGF-23, one of the most important regulators of phosphate
homeostasis, is produced by osteocytes and osteoblasts in response to 1,25(OH)2D3 and when the dietary intake of phosphate is increased. PHEX, DMP1,
and ENPP1 are most likely upstream regulators of FGF23 synthesis because inherited human disorders that are caused by a lack of these proteins are
associatedwithincreasedFGF-23levelsandincreasedurinaryphosphateexcretion. Phosphateis absorbedin thegutfromthe diet,storedin theskeleton,
and excreted by the kidneys. The sodium-dependent phosphate cotransporter NPT2b contributes significantly to the absorption of dietary phosphate,
which is enhanced by 1,25(OH)2D3. FGF-23 activates different FGF receptors when associated with the coreceptor Klotho and it increasesrenal phosphate
clearance by reducing expression of the sodium-dependent phosphate cotransporters NPT2a and NPT2c in the proximal renal tubules. It furthermore
suppresses the renal 1a-hydroxylase and stimulates the 24-hydroxylase activity (not shown) and thus reduces 1,25(OH)2D3 levels through two different
mechanisms. FGF-23 also may act on the parathyroid glands to decrease PTH production (dashed line). PTH activates the PTH/PTHrP receptor (PTHR1) and
therebyincreasesrenalphosphateclearanceand1,25(OH)2D3synthesis.(Modifiedwithpermissionfromref.
(77).)(B)Asrenalfunctiondeclines(CKDstages2
to 4), FGF-23 levels increase, thereby enhancing renal phosphate clearance to help maintain serum phosphate levels within the normal range. Elevated
FGF-23 levels, however, reduce 1,25(OH)2D3 levels and thus contribute to the development of secondary hyperparathyroidism. (C) In patients with end-
stage renal disease (CKD stage 5) treated by dialysis, FGF-23 levels can be dramatically elevated and thus may have ‘‘off-target’’ effects in different tissues.
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mainly in the distal tubules. In this portion of the kidney, the
injection of FGF-23 rapidly induces phosphorylation of MAPK
and expression of the early growth-response gene 1 (Egr-1),
which is accompanied by a reduction in Npt2a expression in
adjacent proximal tubules.
(40) These findings could indicate
either that FGF-23 uses a different signaling pathway in the
proximal tubules or that it induces the secretion of an
‘‘intermediary phosphatonin’’ from the distal tubules that affects
Npt2a (and possibly Npt2c expression) in the proximal tubules
through paracrine mechanisms. Alternatively, low levels of KL
expression in the proximal renal tubules may be sufficient for
mediating the phosphaturic actions of FGF23.
Assays to Measure FGF-23
Serum FGF-23 levels can be measured routinely with immuno-
metric assays that detect either the intact hormone alone (iFGF-
23assay)
(41,42) orwithassays that detectthe intactFGF-23as well
as C-terminal fragments thereof (cFGF-23 assay).
(43) One of the
currently available iFGF-23 assays provides better sensitivity
than the cFGF-23 assay to establish the diagnosis of FGF-23-
dependent hypophosphatemic disorders.
(42) In patients with
ESRD, however, who usually have elevated FGF-23 levels, results
obtainedwith the differentassaysystems arewell correlated and
provide an excellent prediction of FGF-23 bioactivity.
(10,13,44)
Furthermore, Western blot analysis of sera from dialysis patients
has revealed that circulating FGF-23 comprises predominantly
the intact hormone,
(44) suggesting that either of the currently
available immunoassays accurately assesses bioactive FGF-23
and thus is suitable for exploring the pathophysiologic roles of
this novel hormone in patients with impaired renal function.
Increased FGF-23 Bioactivity Enhances
Urinary Phosphate Excretion in Individuals
with Normal Renal Function
Unlike most other fibroblast growth factors, FGF-23 is readily
detected in the circulation of healthy individuals,
(41,43,45) and
serum levels rise in humans and rodents in response to
phosphate loading.
(28–30) These findings make it likely that FGF-
23 is an important regulator of renal phosphate handling in
individuals with normal renal function.
Increased FGF-23 bioactivity is observed in several inherited or
acquireddisorders.TheseincludeADHR,arareinheriteddisorder
that is caused by heterozygous FGF23 missense mutations
involving amino acid residue 176 or 179, which constitute the
recognition/cleavage site for subtilisin-like proprotein conver-
tases; these mutations thus impair intracellular cleavage of full-
lengthFGF-23butdonotroutinelycausesignificantelevationsin
circulating FGF-23 levels.
(46) Serum FGF-23 levels are elevated in
patients with TIO, an acquired disorder that is caused by usually
small, often difficult-to-locate tumors that express abundant
amounts of FGF23 mRNA and protein. These patients often show
majorelevationsinserumFGF-23levelsandconsequentlysevere
hypophosphatemia owing to increased urinary phosphate
excretion and decreased 1,25(OH)2D3 levels.
(41–43,47) Other
inherited disorders with increased or inappropriately normal
FGF-23 levels include X-linked hypophosphatemia (XLH), which
is caused by inactivating mutations in PHEX,
(41,43,45) and two
forms of autosomal recessive hypophosphatemia (ARHP) that
are caused by homozygous mutations in either DMP1
(48,49) or
ENPP1.
(26,27) Other rare disorders that are associated with
increased serum FGF-23 levels include fibrous dysplasia (caused
by heterozygous GNAS mutations that lead to the formation of a
constitutively active Gs-a),
(50) Jansen’s metaphyseal chondro-
dysplaia (caused by heterozygous activating PTHR1 muta-
tions),
(51) osteoglophonic dysplasia (caused by heterozygous
activating FGFR1 mutations),
(52) and the linear nevus sebaceous
syndrome (LNSS; molecular defect unknown).
(53,54)
FGF-23 Enhances Phosphate Excretion in
Early CKD Stages
Circulating FGF-23 levels are already elevated in patients with
CKDstages2and3,thatis,wellbeforethereisacriticalreduction
in functioning nephrons [CKD stages 1 and 2: glomerular
filtration rate (GFR)>60mL/min per 1.73m
2; stage 3: 30 to
59mL/min per 1.73m
2, stage 4: 15 to 29mL/min per 1.73m
2;
stage 5: <15mL/min per 1.73m
2]. This rise in serum FGF-23
concentration appears to be a reflection of an increased
production by osteocytes rather than accumulation because
of impaired renal function, and it precedes any detectable
increase in serum phosphate concentration and the decline in
serum 1,25(OH)2D3 levels.
(24,55,56) In fact, increased FGF-23 levels
inthese early CKD stages are associated with increased fractional
excretion of phosphate, making it likely that enhanced FGF-23
secretion helps to maintain normophosphatemia despite a
reduction in nephron mass (Fig. 1, middle panel). Although
FGF-23 measurements may provide a sensitive biomarker of
abnormal renal phosphate handling in early CKD, it remains
unknown how the osteocyte ‘‘senses’’ subtle abnormalities in
renal tubular phosphate handling and whether a kidney-specific
factor exists that triggers the release of FGF-23 from bone cells in
response to transient elevations in serum phosphorus level or in
response to unspecified disease processes in the kidney.
The elevation in serum FGF-23 levels in CKD stages 2 and 3
most likely precedes the increase in PTH levels, thus raising the
possibilitythatsecondaryhyperparathyroidism develops,atleast
in part, because of an FGF-23-induced reduction in the renal
production of 1,25(OH)2D3, an important negative regulator of
PTH synthesis.
(55,56) On the other hand, FGF-23 was shown in
short-term studies to directly reduce the secretion of PTH in vitro
and in vivo,
(57,58) suggesting that FGF-23 has two competing
effects on PTH synthesis and/or secretion—an indirect effect
through an FGF-23-dependent reduction in 1,25(OH)2D3 syn-
thesis and a direct effect on parathyroid cells, which express
different FGF receptors as well as Klotho and thus can bind
FGF-23 with high affinity. However, the expression levels of
Klotho and FGFRs are reduced in parathyroid tissue of patients
with secondary hyperparathyroidism, which could explain why
FGF-23,evenifpresentatextremelyhighlevels,cannotpreventa
rise in PTH levels.
(59)
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CKD Stage 5
Abnormalities in PTH, calcium, phosphate, and vitamin D explain
some, but not all, of the complex alterations in bone structure
and function that accompany CKD. Traditionally, PTH measure-
mentsrepresented theonly hormonalbiomarker topredict bone
turnover in ESRD patients, and thus they are used to guide
therapy with active vitamin D analogues, calcimimetics, and
phosphate binders. To acknowledge that renal osteodystrophy
affects not only boneturnover, Kidney Disease: Improving Global
Outcomes (KDIGO) introduced a new classification that also
includes bone mineralization and volume (TMV).
(60)
FGF-23 levels were shown recently to correlate with
parameters of altered skeletal mineralization in children with
CKD.
(10,24) Although the mechanisms leading to defective
skeletal mineralization in CKD patients remain to be evaluated,
FGF-23 levels were inversely correlated with osteoid surface,
osteoid volume, and osteoid thickness across the spectrum of
CKD.
(10) FGF-23 is produced by osteocytes and osteoblasts, and
its expressioninbone from patientswith CKD, whowerenaive to
vitamin D therapy, was shown to be markedly elevated; this
increase in immunoreactive FGF-23 occurs, before vitamin D
therapy, very early in the course of CKD, and the amount of FGF-
23 protein in bone cells, particularly in osteocytes, increases
progressively as GFR diminishes.
(24) It is interesting to note that
the expression of DMP1, inactivating mutations in which lead to
increased FGF-23 expression,
(48,49) is also markedly elevated, yet
its expression pattern differs from that of FGF-23.
(24) These
findings provide further evidence for a potential role of bone in
responding to phosphate load by increasing FGF-23 production
early in the course of CKD. In patients treated with dialysis, FGF-
23 thus appears to have a significant role as a biomarker that
predicts some aspects of the abnormalities of bone metabolism
that are observed in this condition and are part of the spectrum
of metabolic bone disease (MBD) associated with CKD.
(60)
Postrenal Transplantation
Hypophosphatemia Is Triggered by FGF-23
Successful renal transplantation frequently corrects many of the
abnormalities in mineral and bone metabolism that develop
during the course of CKD, but hyperparathyroidism frequently
persists and was thought to contribute to the development of
hypercalcemia and hypophosphatemia in the extended post-
transplant period. More recently, however, persistently elevated
FGF-23 levels were observed for prolonged periods of time after
renal transplantation, and these have been associated with
hypophosphatemia and low 1,25(OH)2D3 level independent of
PTH.
(61,62) It is plausible that patients who received a renal
transplant and show persistently increased FGF-23 secretion
despite a well-functioning kidney graft are at risk of accelerated
deterioration of renal function just as nondiabetic CKD patients
without a prior renal transplant
(63); this is an important question
that requires further study. Aside from its effects on mineral ion
homeostasis, FGF-23 levels therefore may help to predict long-
term graft function. Future outcomes studies in transplant
populations are needed to test this hypothesis.
Plausible ‘‘Off-Target’’ Effects of FGF-23
in ESRD
In patients with early stages of CKD, increased FGF-23 levels
reduce 1,25(OH)2D3 formation and are likely to contribute
prominently to maintaining serum phosphate levels within
normal limits.
(55,56) However, in these patients, FGF-23 also may
have systemic ‘‘off-target’’ effects that contribute to cardiovas-
culardisease,aleadingcauseofdeathinbothadultandpediatric
CKD patients. Indeed, several studies involving CKD patients
have suggested recently a pathogenic role of FGF-23 in the
developmentofcardiovascular injurybecausehighFGF-23levels
were found to be associated with vascular calcifications, increas-
ed left ventricular mass index, and left ventricular hypertrophy in
dialysis patients, predialysis patients, and subjects with normal
renal function.
(12,64,65) Furthermore, FGF-23 levels were inde-
pendently associated with increased mortality risk in incident
dialysispatientswithoutconfoundingbyserumphosphatelevels
or a variety of other factors that have been associated with
dialysis mortality previously.
(13) Similarly dramatic findings of a
dose-response type of relationship between FGF-23 and
mortality were made in additional studies investigating long-
term dialysis patients.
(14) In each of these studies, the impact of
serum FGF-23 concentration was independent of serum phos-
phate levels, suggesting that either FGF-23 is superior to serum
phosphate as a biomarker of phosphate-related toxicity or an
increased FGF-23 level by itself has negative biologic con-
sequences.TheclinicalimplicationsofincreasedFGF-23valuesin
dialysis patients remain to be established because therapy with
active vitamin D sterols further increase FGF-23 levels but, on the
other hand, is associated with a survival benefit that is
independent of serum calcium, phosphate, and PTH levels in
dialysis patients.
(66–68) This paradox highlights the needs for
future prospective, randomized trials to evaluate the impact of
vitamin D sterol therapy and FGF-23 levels in patients treated
with maintenance dialysis. Identification of vitamin D analogues
that have untainted survival benefits yet limited effects on the
production of FGF-23 could provide a considerable therapeutic
benefit.
Therapeutic Interventions to Limit the
Putative ‘‘Off-Target’’ Effects of FGF-23
in CKD
As outlined earlier, growing evidence indicates that measure-
ment of FGF-23 may serve as a biomarker that provides evidence
for a disordered mineral ion homeostasis in CKD patients and
predicts abnormal bone mineralization, kidney disease progres-
sion, vascular calcifications, and overall mortality. However,
interpretation of FGF-23 levels depends on the CKD stage and
the specific therapeutic interventions based on the degree
of renal function. Furthermore, it is conceivable that FGF-23
has direct ‘‘off-target’’ effects that contribute to some of the
observed morbidity and mortality in this patient population.
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risk factor for cardiovascular disease and mortality in patients
treated with dialysis
(69) (as well as in predialysis CKD patients
and in individuals without kidney disease; for review, see refs.
(64)
and
(65)). Consistent with the importance of elevated serum
phosphorate levels as predictors of poor outcome, early
treatment of incident hemodialysis patients with phosphate
binders was shown to be associated with a significantly lower
mortality risk.
(64) Interestingly, the survival benefit of early
binder therapy was independent of serum phosphate levels,
suggesting that other factors such as FGF-23 could contribute
to mortality through yet unknown mechanisms. This then raises
the question of whether treatment with phosphate-binding
agents could improve outcome by lowering the FGF-23 levels
in patients with earlier and later stages of CKD, as suggested
recently,
(70–72) and whether additional treatment options could
be envisioned that reduce potential ‘‘off-target’’ effects of
FGF-23.
Phosphate Binders in Early Stages
of CKD?
Currently, therapy with phosphate binders is recommended to
correct hyperphosphatemia; prospective, randomized long-term
trials need to be conducted in patients with CKD stages 2 to 4 to
evaluate whether phosphate binders could lead to a sustained
reductions in serum FGF-23 levels and whether such reductions
would prolong kidney and patient survival and prevent the
developmentofsecondaryhyperparathyroidism, aspredictedby
earlier studies. As a first step, it must be determined whether
phosphate binders effectively lower FGF-23 in this patient
population. A recent pilot study of 40 patients with stage 3 to 4
CKD and normal serum phosphate levels demonstrated that
sevelamer, but not calcium-based binders, lowered FGF-23 over
a 6-week treatment period despite comparable reductions in
urinary phosphate across the two treatment arms.
(72) These
findings confirmed previous reports in animals
(71) and a similar
small study in dialysis patients.
(70) Additional studies with longer
follow-up times are needed to confirm this initial report in stages
2 to 4 and to determine whether the lack of an FGF-23-lowering
effect of calcium was an outlying finding in a small study or
represents a true physiologic difference compared with the non-
calcium-based binders.
In addition to establishing what regimens can best lower
FGF-23 for sustained periods in stages 2 to 4 CKD, it must be
demonstrated that FGF-23 excess represents a risk factor for
adverse outcomes in this population, as suggested by several
investigators. Once additional studies have provided further
evidence supporting the conclusion that FGF-23 is a risk factor
for mortality in different CKD stages, and if FGF-23 can be
lowered effectively with sustainable medical regimens, large
clinical trials should be conducted. The role of dietary phosphate
restriction and possibly niacin administration (which lowers
NPT2b expression and thus gastrointestinal phosphate absorp-
tion
(73)) in such trial also requires significant attention either as
comparator arms or, more likely, as complementary therapies in
a multi-intervention approach to be compared with placebo.
Monoclonal Anti-FGF-23 Antibodies as
Inhibitors of FGF-23 Action in CKD
Therapy with monoclonal anti-FGF-23 antibodies were shown
recently in hyp mice, that is, the murine equivalent of XLH,t o
reduce FGF-23 bioactivity, thereby increasing expression of the
sodium-dependent phosphate cotransporter in the proximal
renal tubules and normalizing serum phosphate levels.
(74) Such
therapy would not be predicted to be helpful in CKD patients
stages 2 to 4; in fact, such an intervention would be expected to
carry considerable risk since increased FGF-23 levels in patients
with early CKD stages are thought to help maintain serum
phosphorus levels within normal limits (see above). Therapy with
monoclonalanti-FGF-23antibodiesinCKDstages2to4probably
would result in hyperphosphatemia because of reduced urinary
phosphate excretion and enhanced 1,25(OH)2D3-dependent
intestinal phosphate absorption. The latter also could lead to a
significant increase in serum calcium that could contribute to
hypercalcemia, as observed in FGF23 and Klotho null mice.
(75,76)
In patients undergoing maintenance dialysis, FGF-23-
mediated renal phosphate elimination is no longer the major
determinant of serum phosphate levels. Therefore, in contrast to
patients with some degree of residual renal function, mono-
clonalanti-FGF-23antibodiesmaybeofpotentialbenefitinESRD
patients if evidence for ‘‘off-target’’ effects of FGF-23 can be
confirmed through different in vitro and in vivo approaches.
Such studies would help to decide whether high FGF-23 levels
are directly contributing to the increased mortality observed
in dialysis patients, in which case treatment with monoclonal
anti-FGF-23 antibodies could be beneficial. There is currently
no possibility to allow long-term survival of nephrectomized
laboratory animals through dialysis treatment, thus making it
impossible to assess the impact of such antibodies on putative
‘‘off-target’’ effects of FGF-23 in the laboratory setting. Therefore,
in vitro approaches need to be developed that can serve as
surrogates to then be tested in humans.
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